Hence an approval in the next one-and-a-half to two years seems unlikely." Chereddi adds, "Hengrui's product is just starting Phase 3 in China, and Innovent's product has approval from the Chinese FDA, but hasn't been filed in India." His conclusion: "Indian generic manufacturers face a limited but real opportunitynot an open market." Shah frames it as a "timing risk, not an inevitability", and flags three gating factors beyond trial requirements: Regulatory scrutiny of novel oral delivery systems, bioavailability concerns specific to Indian populations and intellectual property protection on oral peptide platforms that limits immediate generic replication
Mesenchymal stem cells respond with enhanced trophic factor secretion, including dose-dependent increases in VEGF and bFGF
R.Caspell-GarciaC.CoffeyC
Davioud-Charvet E, Delarue S, Biot C, Schwobel B, Boehme CC, Mussigbrodt A, et al
Moreover, it is a therapy capable of remedying all the symptoms related to the deficiency of this nutrient, which include weakness, a bad mood, and difficulty concentrating
Two months course( 16 injections)
